{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:21:09Z","timestamp":1789438869717,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["229733"],"award-info":[{"award-number":["229733"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.antiviral.2020.104807","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T02:29:35Z","timestamp":1587781775000},"page":"104807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice"],"prefix":"10.1016","volume":"179","author":[{"given":"Yacine","family":"Abed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Fage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liva","family":"Checkmahomed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Venable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.antiviral.2020.104807_bib1","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.13.18-00146","article-title":"Dominant influenza A(H3N2) and B\/Yamagata virus circulation in EU\/EEA, 2016\/17 and 2017\/18 seasons, respectively","volume":"23","author":"Adlhoch","year":"2018","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104807_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/infdis\/jiz418","article-title":"Impact of the baloxavir-resistant polymerase acid I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains","volume":"221","author":"Checkmahomed","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104807_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/v11010006","article-title":"In Vitro Properties and Virulence of contemporary recombinant influenza B viruses harboring mutations of cross-resistance to neuraminidase inhibitors","volume":"11","author":"Fage","year":"2018","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.antiviral.2020.104807_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01081-18","article-title":"Characterization of influenza B virus variants with reduced neuraminidase inhibitor susceptibility","volume":"62","author":"Farrukee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104807_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104807_bib6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104807_bib7","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1128\/JCM.43.8.4139-4146.2005","article-title":"Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor","volume":"43","author":"Hatakeyama","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104807_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104807_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2020.104807_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","volume":"5","author":"Imai","year":"2020","journal-title":"Nat. Microbial."},{"key":"10.1016\/j.antiviral.2020.104807_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa164","article-title":"Treatment-emergent influenza virus PA susbtitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil","author":"Ince","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104807_bib12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104807_bib13","first-page":"9","article-title":"Identification of the I38T PA Substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors","volume":"24","author":"Jones","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2020.104807_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1916825117","article-title":"Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility","author":"Jones","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104807_bib15","first-page":"11","article-title":"Treatment of highly pathogenic H7N9 virus-infected mice with baloxavir marboxil","volume":"15","author":"Kiso","year":"2019","journal-title":"Viruses Nov"},{"key":"10.1016\/j.antiviral.2020.104807_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018","volume":"164","author":"Koszalka","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104807_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104807_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza A, B, C, and D viruses to baloxavir","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104807_bib19","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.96.16.9345","article-title":"Generation of influenza A viruses entirely from cloned cDNAs","volume":"96","author":"Neumann","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2020.104807_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104807_bib21","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104807_bib22","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.5.18-00035","article-title":"Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017\/18 vaccine effectiveness, Canada, January 2018","volume":"23","author":"Skowronski","year":"2018","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104807_bib23","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:21:22Z","timestamp":1778671282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":23,"alternative-id":["S0166354220302217"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104807","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104807"}}